A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Completed · Phase 2 · Has a placebo group

Conditions studied: Scar Prevention, Scar Reduction

In brief

The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.

Key facts

Study ID

NCT00892723

Run by

Capstone Therapeutics

People needed

59

Starts

2009-05-01

Expected to finish

2010-09-01

Last updated by the study team

2012-10-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Keloid scar located below the neck between 1 and 3 cm long and less than 1 cm at its widest point
• Willing to undergo keloid scar excision surgery
• Healthy adult male or non-pregnant female
• Non-diabetic
• Body Mass Index in the range of 18-35
• No clinically significant abnormal values on a full blood safety screen
• Non-smoker and non-nicotine user for the previous six months

You may not qualify if…

• History or clinical evidence of acute or chronic disease
• History of cancer within the last 5 years, except for surgically removed cancers of the skin that are not near the keloid area
• History of anaphylactic shock or anaphylactoid (hypersensitivity) reaction
• Allergy to local anesthesia, including lidocaine and epinephrine
• Dermatologic disorders, except for folliculitis and acne
• On therapy with steroids
• On therapy with a drug that would affect collagen synthesis
• Positive urine test for nicotine or drugs of abuse
• Positive blood test for HIV 1 or 2, hepatitis B or hepatitis C
• Positive blood test for anti-AZX100 antibodies
• Participation in another study within 60 days prior to enrollment
• Blood donation within 7 days before dosing with study drug
• Plasma donation within 3 days before dosing with study drug
• Tattoo within approximately 3 cm of the keloid scar that will be removed
• Apply any lotion or cream on or near the keloid scar that will be removed within 14 days before dosing with study drug
• Use of a tanning bed or tanning light within the 3 months before enrollment
• Intend to use any scar improving product during of the study (1 year)
• History of drug addiction or excessive use of alcohol
• Previous drug treatment of the keloid scar within the last 3 years, or have had any laser, irradiation, or surgical treatment of the keloid scar that will be removed

Where it is running

• Lotus Clinical Research, Inc. — Pasadena, California, United States
• Paddington Testing Company, Inc. — Philadelphia, Pennsylvania, United States
• DermResearch, Inc. — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.